S
Senhwa Biosciences
Drug development company creating innovative therapies for cancer and related diseases
About Senhwa Biosciences
Senhwa Biosciences, Inc., founded in 2012 by Co-founder, President, and CEO Dr. Tai-Sen Soong, is a clinical-stage biopharmaceutical company specializing in the development of targeted therapies for oncology. The company operates with a strategic focus on DNA Damage Response (DDR), aiming to exploit the vulnerabilities of cancer cells. Headquartered in New Taipei City, Taiwan, with a key operational subsidiary in San Diego, California, Senhwa is publicly traded on the Taipei Exchange (TPEx: 6492).
The company's business model centers on identifying and advancing promising drug candidates through to clinical proof-of-concept, a strategy designed to de-risk development and efficiently use resources from the global pharmaceutical ecosystem. Senhwa's revenue is primarily generated through partnerships, licensing agreements, and collaborations with research institutions. A significant milestone was achieved in December 2013 when the company raised $17 million in a Series B financing round, enabling the progression of its key assets into clinical trials.
Senhwa's drug pipeline is led by two first-in-class small molecule compounds, Pidnarulex (CX-5461) and Silmitasertib (CX-4945). Pidnarulex is an investigational drug that functions by stabilizing G-quadruplex (G4) structures in the DNA of cancer cells. This action is designed to trigger replication-dependent DNA damage, leading to cancer cell death, particularly in tumors with BRCA1/2 mutations or other homologous recombination deficiencies (HRD). The U.S. National Cancer Institute (NCI) is sponsoring clinical trials for CX-5461 in advanced solid tumors and MYC-aberrant lymphoma, which significantly reduces Senhwa's R&D expenditures.
Silmitasertib (CX-4945) is a selective inhibitor of the CK2 protein kinase, which plays a role in DNA repair mechanisms. By inhibiting CK2, Silmitasertib enhances the efficacy of DNA-damaging chemotherapy agents. Clinical trials are evaluating its potential in treating cholangiocarcinoma and basal cell carcinoma, with promising results in patients who have failed other therapies. Beyond oncology, interim findings have prompted a strategic shift to explore CX-4945's potential as a treatment for HIV, with plans for a new formulation to improve patient tolerability.
The management team, led by Chairman Mr. Benny T. Hu and CEO Dr. Tai-Sen Soong, possesses extensive experience in drug development, investment, and corporate management. Dr. Soong has a 30-year background in life science operations and investment, including leadership roles at CDIB and founding roles in other pharmaceutical ventures. Mr. Hu is a seasoned entrepreneur and professional manager, previously leading China Development Industrial Bank (CDIB) and expanding its investment portfolio significantly.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Jul 2026 | $16M | — | Global Emerging Markets | ↗ |
| IPO✓Exit | Apr 2017 | $45M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Senhwa Biosciences is 190 monthly website visits, down 88.8% over the last three months. Senhwa Biosciences's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Senhwa Biosciences in the Taipei ecosystem
The Senhwa Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
WI Harper Group- HPH&Q Asia Pacific
Morningside
Series B and later1 investor entered at this stage
Global Emerging Markets
Other known investors2 additional known investors
- BMBlack Marble Capital Management
Cathay Venture
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Senhwa Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Senhwa Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









